TCG Crossover Management, LLC holds a focused book of 49 stocks worth $3.5B as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Biocryst Pharmaceuticals Inc and trimmed Abivax Sa-ADR. Their largest long position is Abivax Sa-ADR at 21% of the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1839948/holdings"
Use Arkolith to show TCG Crossover Management, LLC's latest holdings, largest changes, and filing provenance.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Abivax Sa American Depositary Shares ADRS | $721.7M | 6.48M | 20.6% | ▼−8.9% Reduced · −631K sh | |
| 2 | CG Oncology Inc COMM | $248.4M | 3.67M | 7.1% | —Held | |
| 3 | Tango Therapeutics Inc COMM | $220.3M | 10.53M | 6.3% | ▼−17% Reduced · −2.2M sh | |
| 4 | Cogent Biosciences Inc COMM | $190.4M | 4.95M | 5.4% | ▼−16% Reduced · −921K sh | |
| 5 | Centessa Pharmaceuticals PLC ADRS | $170.3M | 4.29M | 4.9% | —Held | |
| 6 | Dianthus Therapeutics Inc COMM | $140.7M | 1.68M | 4.0% | —Held | |
| 7 | Tyra Biosciences Inc COMM | $124.4M | 3.25M | 3.6% | ▲+12% Added · +351K sh | |
| 8 | Immunovant Inc COMM | $110.7M | 4.46M | 3.2% | ▲+168% Added · +2.8M sh | |
| 9 | Biocryst Pharmaceuticals Inc COMM | $104.9M | 11.02M | 3.0% | ▲New New position | |
| 10 | Mirum Pharmaceuticals Inc COMM | $98.1M | 1.06M | 2.8% | ▲17× Added · +1.0M sh | |
| 11 | Vor Biopharma Inc COMM | $96.5M | 5.67M | 2.8% | ▲New New position | |
| 12 | Spyre Therapeutics Inc COMM | $95.9M | 1.90M | 2.7% | —Held | |
| 13 | Amylyx Pharmaceuticals Inc COMM | $86.8M | 6.24M | 2.5% | —Held | |
| 14 | Disc Medicine Inc COMM | $85.8M | 1.34M | 2.5% | ▲New New position | |
| 15 | Dyne Therapeutics Inc COMM | $83.7M | 4.62M | 2.4% | —Held | |
| 16 | Monte Rosa Therapeutics Inc COMM | $76.0M | 4.62M | 2.2% | —Held | |
| 17 | Savara Inc COMM | $67.5M | 12.36M | 1.9% | —Held | |
| 18 | Revolution Medicines Inc COMM | $56.1M | 576.5K | 1.6% | ▲+32% Added · +140K sh | |
| 19 | Kodiak Sciences Inc COMM | $55.1M | 1.45M | 1.6% | —Held | |
| 20 | LB Pharmaceuticals Inc COMM | $45.3M | 1.84M | 1.3% | ▲+5.4% Added · +94K sh | |
| 21 | Surrozen Inc COMM | $42.9M | 1.47M | 1.2% | ▲New New position | |
| 22 | Adc Therapeutics Sa COMM | $42.7M | 11.39M | 1.2% | —Held | |
| 23 | Relay Therapeutics Inc COMM | $42.5M | 4.27M | 1.2% | ▲+33% Added · +1.1M sh | |
| 24 | Fulcrum Therapeutics Inc COMM | $40.3M | 5.25M | 1.2% | —Held | |
| 25 | Biohaven Ltd COMM | $39.2M | 4.63M | 1.1% | —Held | |
| 26 | Century Therapeutics Inc COMM | $39.0M | 17.75M | 1.1% | ▲New New position | |
| 27 | Tectonic Therapeutic Inc COMM | $37.2M | 1.20M | 1.1% | ▲New New position | |
| 28 | Perspective Therapeutics Inc COMM | $33.0M | 7.92M | 0.9% | ▲New New position | |
| 29 | Xencor Inc COMM | $29.6M | 2.45M | 0.8% | —Held | |
| 30 | Entrada Therapeutics Inc COMM | $28.9M | 2.29M | 0.8% | ▲+9.5% Added · +199K sh | |
| 31 | Alx Oncology Holdings Inc COMM | $26.1M | 13.01M | 0.7% | ▲New New position | |
| 32 | Arvinas Holding Co LLC COMM | $25.3M | 2.39M | 0.7% | ▼−10% Reduced · −279K sh | |
| 33 | Janux Therapeutics Inc COMM | $24.9M | 1.79M | 0.7% | —Held | |
| 34 | Agomab Therapeutics NV ADRS | $21.5M | 2.05M | 0.6% | ▲New New position | |
| 35 | Alector Inc COMM | $21.5M | 10.00M | 0.6% | —Held | |
| 36 | MBX Biosciences Inc COMM | $19.4M | 650.0K | 0.6% | —Held | |
| 37 | Silence Therapeutics PLC ADRS | $16.0M | 3.03M | 0.5% | —Held | |
| 38 | Liquidia Technologies Inc COMM | $15.2M | 403.0K | 0.4% | ▼−76% Reduced · −1.3M sh | |
| 39 | Ocular Therapeutix Inc COMM | $14.0M | 1.65M | 0.4% | ▼−71% Reduced · −4.1M sh | |
| 40 | Avalo Therapeutics Inc COMM | $11.0M | 738.4K | 0.3% | ▲+53% Added · +255K sh | |
| 41 | Urogen Pharma Ltd COMM | $7.3M | 405.4K | 0.2% | ▼−43% Reduced · −312K sh | |
| 42 | Monopar Therapeutics Inc COMM | $7.2M | 132.1K | 0.2% | ▼−6.9% Reduced · −10K sh | |
| 43 | Context Therapeutics Inc COMM | $7.0M | 2.68M | 0.2% | ▲New New position | |
| 44 | Structure Therapeutics Inc ADRS | $6.8M | 140.4K | 0.2% | ▼−85% Reduced · −780K sh | |
| 45 | Cullinan Therapeutics Inc COMM | $5.8M | 406.8K | 0.2% | ▲New New position | |
| 46 | Korro Bio Inc COMM | $4.7M | 416.3K | 0.1% | —Held | |
| 47 | Leonabio Inc COMM | $4.7M | 464.4K | 0.1% | —Held | |
| 48 | Upstream Bio Inc COMM | $1.6M | 181.1K | 0.0% | ▼−76% Reduced · −563K sh | |
| 49 | Vistagen Therapeutics Inc COMM | $1.5M | 2.68M | 0.0% | —Held |
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 49 | $3.5B | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 17, 2026 | 43 | $3.0B | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 17, 2025 | 40 | $2.0B | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 38 | $875.5M | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 14, 2025 | 38 | $733.1M | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 38 | $1.0B | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 14, 2024 | 36 | $1.2B | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 14, 2024 | 32 | $959.5M | 13F-HR |
| Q1 2024 | Mar 31, 2024 | May 15, 2024 | 33 | $1.3B | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 14, 2024 | 29 | $901.7M | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 14, 2023 | 26 | $679.1M | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Aug 14, 2023 | 22 | $609.8M | 13F-HR |
| Q1 2023 | Mar 31, 2023 | May 15, 2023 | 22 | $513.0M | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Feb 14, 2023 | 21 | $566.6M | 13F-HR |
| Q3 2022 | Sep 30, 2022 | Nov 14, 2022 | 21 | $333.4M | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Aug 15, 2022 | 22 | $235.4M | 13F-HR |
| Q1 2022 | Mar 31, 2022 | May 16, 2022 | 20 | $249.1M | 13F-HR |
| Q4 2021 | Dec 31, 2021 | Feb 18, 2022 | 15 | $213.6M | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.